Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19

Princess Nourah Bint Abdulrahman University

Overview

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. At this time, there are no specific vaccines or treatments for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments Drugs used to treat malaria infection has shown to be beneficial for many other diseases, including viral infections. In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab COVID-19 patients. Investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the COVID -19 patients. In improving their condition and clearing the virus load,

In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab COVID-19 patients. investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the COVID -19 patients. In improving their condition and clearing the virus load, investigators are testing two groups the one that will take the drug and then compare them to a placebo group that will not take any drug for the treatment in a blinded fashion made by randomization done by our pharmacy team so investigators eliminate risk of bias. Our expectation is to find a total reduction of the hospital stay to 7 days instead of 14 days currently indicating the effectiveness of the medication in eradicating the virus.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Conditions

Covid 19 Positive Corona Virus Infection

Interventions

Artemisinin / ArtesunateDRUG

testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative

placeboOTHER

placebo or sham drug will be given to the second arm

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patient age more than 18 and less than 60 years * Symptomatic , positive swab covid-19 patients * Patients who have mild to moderate symptoms * Patients who have no risk factors like * Patients who is not on other medications rather those on supportive care Exclusion Criteria: * · Patients who have sever disease- shortness of breath, sick patients or admitted in ICU * Patients who are receiving ventilation supports * High risk group like :- age more than 60 years, chronic heart diseases, chronic lungs diseases, diabetes, immunocompromised diseases or on immune suppression medications or pregnant women * Patients who are on other medications which used as treatment for covid 19

Locations (1)

Princess Nourah Bint Abdulrahman Univeristy

Riyadh, Central, Saudi Arabia

Outcomes

Primary Outcomes

length of stay in hospital

absence of the virus shedding evidenced by negative swabs

Time frame: within the first 6 days intervention

Secondary Outcomes

number of ICU admission

reduction of morbidity and mortality

Time frame: 14 days

resolution of symptoms

finding the time that the symptoms disappear

Time frame: 6 days - 10 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.